Also around $50M fund in total R&D rebate for 2024 and 2025 given the amount of R&D spent in the last few years. The clinical trial update for OASIS is expected to be released sometime in H2, this is very important as LC said the big US Instos are looking at this IP which could open 90% of the solid cancer market and will be the first update and then there will be data released use to apply for registrational clinical trial for Azer-Cel end of this year or early next year.
IMU Price at posting:
2.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)